FREE Board Certified Ophthalmologist Glaucoma Management Questions and Answers Flashcards
6 cards from real Board Certified Ophthalmologist practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 FREE Board Certified Ophthalmologist Glaucoma Management Questions and Answers flashcards as text
In a patient with pseudoexfoliation glaucoma, which characteristic finding is seen on slit-lamp examination?
Answer: White flaky material on the anterior lens capsule
Pseudoexfoliation glaucoma is characterized by white, dandruff-like fibrillar material deposited on the anterior lens capsule and pupillary margin.
Which minimally invasive glaucoma surgery (MIGS) device works by enhancing trabecular outflow through Schlemm's canal?
Answer: iStent
The iStent is a trabecular micro-bypass device that creates a direct pathway from the anterior chamber into Schlemm's canal.
What is the most significant risk factor for the development of normal-tension glaucoma?
Answer: Disc hemorrhage and thin central corneal thickness
Disc hemorrhages and thin central corneal thickness are strongly associated with normal-tension glaucoma and predict progression.
A patient undergoes trabeculectomy and develops a shallow anterior chamber with low IOP on postoperative day one. What is the most likely cause?
Answer: Overfiltration through the bleb
Early postoperative hypotony with a shallow chamber after trabeculectomy most commonly results from overfiltration through the surgical site.
Which class of glaucoma medication is contraindicated in patients with a history of cystoid macular edema following cataract surgery?
Answer: Prostaglandin analogs
Prostaglandin analogs can exacerbate or trigger cystoid macular edema, particularly in pseudophakic eyes with disrupted posterior capsule.
What is the mechanism of action of netarsudil, a newer glaucoma medication?
Answer: Rho kinase inhibition leading to decreased trabecular meshwork resistance and reduced episcleral venous pressure
Netarsudil is a rho kinase inhibitor that lowers IOP by decreasing trabecular meshwork outflow resistance and reducing episcleral venous pressure.